Editorial commentaries

473 Treating multiple sclerosis with vitamin D J Chataway

474 Early recognition of POEMS syndrome: what is the role of clinical neurophysiology? K Arimura

Impact commentaries

475 Polynuropathy in critically ill patients C F Bolton

Neuromuscular disease

476 Different neurological and physiological profiles in POEMS syndrome and chronic inflammatory demyelinating polynuropathy S Nasu, S Misawa, Y Sekiguchi, K Shibuya, K Kanai, Y Fujimaki, S Ohmori, S Mitsuma, S Koga, S Kawai

480 Uniform demyelination and more severe axonal loss distinguish POEMS syndrome from CIDP M L Mauermann, E J Sorenson, A Dispensieri, J Mandrekas, G A Suarez, P J Dyck, P J B Dyck

Neuro-ophthalmology

488 Update on the pathophysiology and management of idiopathic intracranial hypertension V Biousse, B B Bruce, N J Newman

Neuropsychiatry

495 Depression: an inflammatory illness? R Krishnadas, J Cavanagh

Neurosurgery

503 Who needs a Wada test? Present clinical indications for amobarbital procedures K Wagner, C Hader, B Metternich, F Buschmann, R Schwarzwal, A Schulze-Bonhage


Cognitive neurology


522 Cognitive and metabolic correlates of emotional vulnerability in patients with temporal lobe epilepsy L Lanteaume, E Guedj, M Bastien-Tonizzo, A Magalahaes, O Mundler, F Bartolomei

Cerebrovascular disease

531 Regional differences in incidence and patient characteristics of moyamoya disease: a systematic review R Kleinlog, L Regli, G J E Rinkel, C J M Kliu

537 Thrombolytic therapy for ischaemic stroke in patients using warfarin: a systematic review and meta-analysis I Medema, G J Luijckx, J De Keyser, M Koch, M Vytenboogaart

541 Additional risk of hypertension and smoking for aneurysms in people with a family history of subarachnoid haemorrhage I Rassing, D J Nieuwkamp, A Algra, G J E Rinkel

543 Neurological complications of carotid revascularisation T Y Wu, N E Anderson, P A Barber

Pain

551 Pain perception in humans: use of intraepidermal electrical stimulation K Inui, R Kakigi
Neurodegeneration
557  Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial
E Verstraete, J H Veldink, M H B Huisman, T Draak, E V Uijtendaal, A J van der Kooi, H J Schelhaas, M de Visser, I van der Tweel, L H van den Berg

Multiple sclerosis
565  A randomised, double blind, placebo controlled trial with vitamin D₃ as an add on treatment to interferon β-1b in patients with multiple sclerosis

PostScript
572  Letters
576  Correction

Neurological picture
487  Increased muscle FDG-PET uptake in dermatomyositis
D Renard, L Chiper, L Collombier, P Labauge

529  Distinctive MRI abnormalities in a man with dentatorubral-pallidoluysian atrophy
M Simpson, A Smith, H Kent, R Roxburgh